Business Model Canvas: TEX44-CPT1B Genetic Screening Panel
A targeted genetic screening panel to identify biallelic variants in TEX44 and CPT1B, and potentially other axonemal genes, in men with unexplained asthenozoospermia. The test aims to differentiate between mitochondrial sheath defects and broader ciliary dyskinesia.
The Business Model Canvas reveals a high-specialization diagnostic tool that shifts from a simple two-gene test to a differential diagnostic panel. Success depends on integrating with large-scale clinical labs to reach a niche patient population where the primary value is precise genetic counseling rather than a change in the immediate treatment (ICSI).
Key Partners3
Key Activities3
Key Resources3
Value Propositions3
Customer Relationships2
Channels3
Customer Segments3
Cost Structure3
Revenue Streams2
The idea identifies specific high-value customers like Mayo Clinic and LabCorp, making it appropriate to map out the value proposition and revenue streams. · Generated 2026-08-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated